Diagnostic HYBRIDS
-
Can Interthyr be Ohio U’s next commercialization success story?
While there’s plenty of optimism surrounding Interthyr, it’ll be awhile before university officials know what kind of potential they’re sitting on. No human testing of the company’s drug candidate for cancer and autoimmune disorders has occurred yet, and it’s unlikely to happen until 2012.
-
Diagnostic Hybrids gets Chinese OK for virus test
Ohio University spinoff Diagnostic Hybrids Inc. has received Chinese regulatory approval to sell a respiratory […]
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Night Read (Ohio): Akron now (officially) has a biomedical district
Akron now has a biomedical district, according to the Akron Beacon Journal. With a few minor changes, city council approved legislation Monday that outlined the district — changing it from concept to reality — and made several zoning changes within the area that encompasses the city’s three downtown hospitals and the University of Akron.
-
Quidel Corp. completes acquisition of Diagnostic Hybrids in Athens, Ohio, for $130M
San Diego diagnostic test maker Quidel Corp. has closed its acquisition of Diagnostic Hybrids Inc. for about $130 million in cash. Announced in mid-January, the acquisition is expected to add depth and innovation to Quidel’s line of rapid, point-of-care tests for pregnancy, infectious diseases, cancer, bone health and autoimmune disorders.
-
Night Read (Ohio): Tennessee hospital looks to buy Forum Health?
A sale of Youngstown’s Forum Health, which is reorganizing under Chapter 11 bankruptcy protection, to Nashville, Tenn., hospital system Ardent Health Services hinges on successful negotiations with unions representing about 3,500 Forum workers, unnamed sources told the Tribune Chronicle.
-
Night Read (Ohio): Austen BioInnovation Institute partners with Orthopaedic Research Laboratories
The Austen BioInnovation Institute in Akron has struck a strategic partnership with Cleveland orthopedic device testing and design firm Orthopaedic Research Laboratories to discover, develop and commercialize novel technologies and solutions that advance orthopedic care.
-
Diagnostic HYBRIDS gets FDA OK for fast-acting flu, cold kit
The company says its D3 FastPoint Respiratory Virus Identification Kit can within 30 minutes detect influenza A, influenza B, respiratory syncytial virus, human metapneumovirus, adenovirus and parainfluenza viruses from a patient’s specimen. The company also says its technology allows two respiratory viruses to be detected in a single slide.
-
Diagnostic HYBRIDS test is not approved to detect swine flu virus
“The D3 Ultra kit has been shown to detect the 2009 H1N1 influenza A virus in two culture isolates; the performance characteristics of this device with clinical specimens that are positive for the 2009 H1N1 influenza A virus have not been established,” the company stated in a press release. “The D3 Ultra kit can distinguish between influenza A and B viruses, but it cannot differentiate influenza subtypes.”
-
Diagnostic Hybrids gets FDA clearance for thyroid test
The U.S. Food and Drug Administration has cleared for market a new thyroid test by Diagnostic HYBRIDS, the diagnostic test developer. The test, Thyretain TSI Reporter BioAssay, could lead to earlier diagnoses and management of Graves’ disease.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
The minds of Midwest VCs: Reform, commercialization czars and beware the gullible angel investor
Eight venture capitalists gathered Thursday evening at TechColumbus to discuss bioscience innovation in the state. The audience included a mix of start ups, portfolio companies and research institutions trying to navigate their way into the panelists’ pockets.
-
Q & A: Diagnostic HYBRIDS will expand through thyroid, HIV tests
The Athens, Ohio, company hopes to release kits related to Graves Disease and in 2010 its first HIV detection kit. It’s also preparing a kit to detect thyroid cancer. “We’re a very innovative company trying to be a very successful diagnostic company,” company President David Scholl said.
-
FDA approves new Diagnostic HYBRIDS kit, completes respiratory virus line
The approval completes a line of kits from Diagnostic HYBRIDS to detect other respiratory viruses. Respiratory kits make up the company’s top revenue stream.
-
CWRU licenses AIDS research to Diagnostic HYBRIDS
The innovation determines the drug resistance and disease strength of the virus. Researchers think the approach can be used to better develop a vaccine.